64 related articles for article (PubMed ID: 24676753)
1. Prognosis Related to Metastatic Burden Measured by ¹⁸F-Fluorocholine PET/CT in Castration-Resistant Prostate Cancer.
Kwee SA; Lim J; Watanabe A; Kromer-Baker K; Coel MN
J Nucl Med; 2014 Jun; 55(6):905-10. PubMed ID: 24676753
[TBL] [Abstract][Full Text] [Related]
2. Early outcome prediction on 18F-fluorocholine PET/CT in metastatic castration-resistant prostate cancer patients treated with abiraterone.
De Giorgi U; Caroli P; Burgio SL; Menna C; Conteduca V; Bianchi E; Fabbri F; Carretta E; Amadori D; Paganelli G; Matteucci F
Oncotarget; 2014 Dec; 5(23):12448-58. PubMed ID: 25504434
[TBL] [Abstract][Full Text] [Related]
3. A prospective study on the early evaluation of response to androgen receptor-targeted agents with
Mollica V; Marchetti A; Fraccascia N; Nanni C; Tabacchi E; Malizia C; Argalia G; Rosellini M; Tassinari E; Paccapelo A; Fanti S; Massari F
ESMO Open; 2024 May; 9(5):103448. PubMed ID: 38718704
[TBL] [Abstract][Full Text] [Related]
4. Validating the total illness burden index for prostate cancer (TIBI-CaP) in men with castration-resistant prostate cancer: data from TRUMPET.
Flanders SC; Kim J; Wilson S; Braziunas J; Greenfield S; Billimek J; Lechpammer S; Lin DW; Karsh L; Quinn DI; Shevrin D; Shore ND; Symanowski JT; Penson DF
Future Oncol; 2018 Mar; 14(6):527-536. PubMed ID: 29417827
[TBL] [Abstract][Full Text] [Related]
5. ESTIMATING PERSON-CENTERED TREATMENT (PeT) EFFECTS USING INSTRUMENTAL VARIABLES: AN APPLICATION TO EVALUATING PROSTATE CANCER TREATMENTS.
Basu A
J Appl Econ (Chichester Engl); 2014; 29(4):671-691. PubMed ID: 25620844
[TBL] [Abstract][Full Text] [Related]
6. Event-free survival after
Ceci F; Rovera G; Iorio GC; Guarneri A; Chiofalo V; Passera R; Oderda M; Dall'Armellina S; Liberini V; Grimaldi S; Bellò M; Gontero P; Ricardi U; Deandreis D
Eur J Nucl Med Mol Imaging; 2022 Jul; 49(9):3257-3268. PubMed ID: 35217883
[TBL] [Abstract][Full Text] [Related]
7. Value of 18F-fluorocholine PET/CT in predicting response to radical radiotherapy in patients with localized prostate cancer.
Sepulcri M; Fusella M; Cuppari L; Zorz A; Paiusco M; Evangelista L
Clin Transl Radiat Oncol; 2021 Sep; 30():71-77. PubMed ID: 34409175
[TBL] [Abstract][Full Text] [Related]
8. Prognostic and Theranostic Applications of Positron Emission Tomography for a Personalized Approach to Metastatic Castration-Resistant Prostate Cancer.
Filippi L; Frantellizzi V; Chiaravalloti A; Pontico M; De Feo MS; Corica F; Montebello M; Schillaci O; De Vincentis G; Bagni O
Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33809749
[TBL] [Abstract][Full Text] [Related]
9. Prognostic Value of
Quaquarini E; D'Ambrosio D; Sottotetti F; Gallivanone F; Hodolic M; Baiardi P; Palumbo R; Vellani C; Canevari C; Bernardo A; Castiglioni I; Porta C; Trifirò G
Contrast Media Mol Imaging; 2019; 2019():4325946. PubMed ID: 31049043
[TBL] [Abstract][Full Text] [Related]
10.
Giovacchini G; Guglielmo P; Mapelli P; Incerti E; Gajate AMS; Giovannini E; Riondato M; Briganti A; Gianolli L; Ciarmiello A; Picchio M
Eur J Nucl Med Mol Imaging; 2019 Apr; 46(4):921-929. PubMed ID: 30631911
[TBL] [Abstract][Full Text] [Related]
11. Assessment of Skeletal Tumor Load in Metastasized Castration-Resistant Prostate Cancer Patients: A Review of Available Methods and an Overview on Future Perspectives.
Fiz F; Dittman H; Campi C; Morbelli S; Marini C; Brignone M; Bauckneht M; Piva R; Massone AM; Piana M; Sambuceti G; la Fougère C
Bioengineering (Basel); 2018 Jul; 5(3):. PubMed ID: 30060546
[TBL] [Abstract][Full Text] [Related]
12. Positron emission tomography in prostate cancer: An update on state of the art.
Das CJ; Razik A; Sharma S
Indian J Urol; 2018; 34(3):172-179. PubMed ID: 30034126
[TBL] [Abstract][Full Text] [Related]
13. Fluorine-18-fluorocholine PET/CT parameters predictive for hematological toxicity to radium-223 therapy in castrate-resistant prostate cancer patients with bone metastases: a pilot study.
Vija Racaru L; Sinigaglia M; Kanoun S; Ben Bouallègue F; Tal I; Brillouet S; Bauriaud-Mallet M; Zerdoud S; Dierickx L; Vallot D; Caselles O; Gabiache E; Pascal P; Courbon F
Nucl Med Commun; 2018 Jul; 39(7):672-679. PubMed ID: 29790867
[TBL] [Abstract][Full Text] [Related]
14. Circulating androgen receptor combined with 18F-fluorocholine PET/CT metabolic activity and outcome to androgen receptor signalling-directed therapies in castration-resistant prostate cancer.
Conteduca V; Scarpi E; Caroli P; Salvi S; Lolli C; Burgio SL; Menna C; Schepisi G; Testoni S; Gurioli G; Paganelli G; Casadio V; Matteucci F; De Giorgi U
Sci Rep; 2017 Nov; 7(1):15541. PubMed ID: 29138500
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value of 18F-choline PET/CT metabolic parameters in patients with metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide.
Caroli P; De Giorgi U; Scarpi E; Fantini L; Moretti A; Galassi R; Celli M; Conteduca V; Rossi L; Bianchi E; Paganelli G; Matteucci F
Eur J Nucl Med Mol Imaging; 2018 Mar; 45(3):348-354. PubMed ID: 29110067
[TBL] [Abstract][Full Text] [Related]
16. Therapy assessment in prostate cancer using choline and PSMA PET/CT.
Ceci F; Herrmann K; Hadaschik B; Castellucci P; Fanti S
Eur J Nucl Med Mol Imaging; 2017 Aug; 44(Suppl 1):78-83. PubMed ID: 28540419
[TBL] [Abstract][Full Text] [Related]
17. PET and PET/CT with radiolabeled choline in prostate cancer: a critical reappraisal of 20 years of clinical studies.
Giovacchini G; Giovannini E; Leoncini R; Riondato M; Ciarmiello A
Eur J Nucl Med Mol Imaging; 2017 Sep; 44(10):1751-1776. PubMed ID: 28409220
[TBL] [Abstract][Full Text] [Related]
18. Multimodality imaging using proton magnetic resonance spectroscopic imaging and
Shukla-Dave A; Wassberg C; Pucar D; Schöder H; Goldman DA; Mazaheri Y; Reuter VE; Eastham J; Scardino PT; Hricak H
World J Radiol; 2017 Mar; 9(3):134-142. PubMed ID: 28396727
[TBL] [Abstract][Full Text] [Related]
19. Positron emission tomography in imaging evaluation of staging, restaging, treatment response, and prognosis in prostate cancer.
Jadvar H
Abdom Radiol (NY); 2016 May; 41(5):889-98. PubMed ID: 27193789
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
